Our work yields essential insights into the mechanisms underlying PI3K inhibitor resistance, which often involves activation of receptor tyrosine kinase signaling, and identifies SHP2 as a crucial factor in this process in breast cancer cells. This evidence concerns the gene NTRK1 and breast cancer.